The University of Liege has signed a new license agreement with Chinese animal health company Ningbo SanSheng Biological Technology to develop and commercialize a vaccine against Anguillid herpesvirus 1 (AngHV-1), a deadly virus affecting eels and causing significant losses in aquaculture. Developed by the Virology and Vaccinology Laboratory at the Faculty of Veterinary Medicine under Professor Alain Vanderplasschen, the recombinant live attenuated vaccine can be administered via immersion, offering a practical and effective solution for large-scale eel farming.
This vaccine addresses both economic and conservation challenges, protecting farmed eels and potentially aiding the preservation of wild European eel populations. The agreement with Ningbo SanSheng targets the Asian market, while the University of Liege seeks partners to expand access in Europe and the Americas. The research has been supported by the WEL Research Institute and the European Maritime and Fisheries Fund.
Source: University of Liege
About the Author
